853. Deputy James Geoghegan asked the Minister for Health if the drug skyclarys (omaveloxolone) used for the treatment of Friedreich's ataxia will be made available under licence in Ireland; and if she will make a statement on the matter. [28209/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
872. Deputy Aindrias Moynihan asked the Minister for Health the measures being taken in digital interventions by HPRA to shut down websites, social media and e-commerce listings promoting illegal medicines in Ireland; and if she will make a statement on the matter. [28386/26]
886. Deputy Pádraig Rice asked the Minister for Health further to Parliamentary Question No. 423 of 5 February 2026, the status of an application for pricing and reimbursement (details supplied); if the HSE is still considering this application; the projected timeline for a decision; and if she will make a statement on the matter. [28668/26]
282. Deputy Natasha Newsome Drennan asked the Minister for Health to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [27745/26]
332. Deputy Emer Currie asked the Minister for Health the latest update on the accessibility of skyclarys for the treatment of Friedreich’s ataxia; the timeline as to when the HSE senior leadership team will make a decision; and if she will make a statement on the matter. [27367/26]
339. Deputy Peter 'Chap' Cleere asked the Minister for Health if she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an 'unmet need' as outlined in the National Rare Disease Strategy 2025-2030. [27404/26]
340. Deputy Peter 'Chap' Cleere asked the Minister for Health her views on way in which the current delay with the skyclarys reimbursement negotiations aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [27405/26]
360. Deputy Ken O'Flynn asked the Minister for Health whether her Department has established a formal, national definition of “clinically critical medicines”; and if so, the criteria used to determine such classification; and if she will provide the current list of medicines designated under this definition. [27514/26]
361. Deputy Ken O'Flynn asked the Minister for Health whether a formal risk-assessment or stratification model is in place to categorise medicines by clinical criticality and patient safety risk; and the methodology used within such a model; and if she will outline how it is applied in practice across the health service. [27515/26]
362. Deputy Ken O'Flynn asked the Minister for Health whether respiratory emergency medicines, including salbutamol nebules, are classified as clinically critical within any national prioritisation system; and if she will detail the specific safeguards applied to ensure continuity of supply for such medicines. [27516/26]
363. Deputy Ken O'Flynn asked the Minister for Health the governance structure underpinning the Medicines Criticality Assessment Group; the decision-making authority within that structure; and the level at which final determinations are made in relation to supply risk mitigation actions. [27517/26]
364. Deputy Ken O'Flynn asked the Minister for Health whether formal escalation thresholds exist within the medicines shortages framework based on clinical risk levels; and if so, the criteria for escalation; and the actions triggered at each level. [27518/26]
365. Deputy Ken O'Flynn asked the Minister for Health whether minimum stockholding requirements or buffer stock policies are in place for medicines deemed clinically critical; and the basis on which such levels are determined; and the mechanisms used to monitor compliance. [27519/26]
366. Deputy Ken O'Flynn asked the Minister for Health whether national early warning or predictive monitoring systems are in place to identify potential shortages of clinically critical medicines in advance; and if she will outline the data sources and indicators used within such systems. [27520/26]
368. Deputy Ken O'Flynn asked the Minister for Health which body holds ultimate accountability for ensuring continuity of supply of clinically critical medicines at national level; and the oversight mechanisms in place to monitor performance against this responsibility. [27522/26]
369. Deputy Ken O'Flynn asked the Minister for Health the preparatory steps that have been taken to align national policy with the forthcoming European Union list of critical medicines; and whether an interim national list is in operation pending the introduction of EU measures. [27523/26]
2626. Deputy George Lawlor asked the Minister for Health the current position regarding her Department's discussions with the IPU in relation to the charging of GMS patients for the provision of MDS/Blister packs; her views on whether that providing required medication in blister packs to vulnerable patients is an essential health service to ensure proper dosage is received and to avoid overdosing and underdosing; an…
2769. Deputy Richard Boyd Barrett asked the Minister for Health for an update on the approval of omaveloxolone for the treatment of Friedrich's ataxia. [24114/26]
2936. Deputy Paula Butterly asked the Minister for Health to respond to correspondence (details supplied) regarding the application of charges for blister packs, noting that phased dispensing is essential for patient safety; and if she will make a statement on the matter. [24861/26]
2985. Deputy Denise Mitchell asked the Minister for Health if consideration will be given to adding the drug skyclarys which is used in the treatment of Friedreich's ataxia to the drugs payment scheme; and if she will make a statement on the matter. [25182/26]
2994. Deputy Edward Timmins asked the Minister for Health the steps that can be taken to bring Ireland in line with other European countries for the treatment of Friedreich’s ataxia (details supplied); and if she will make a statement on the matter. [25231/26]
2996. Deputy Aindrias Moynihan asked the Minister for Health for clarification on the stage of a medication (details supplied) under assessment to be included on the drugs payment scheme; and if she will make a statement on the matter. [25240/26]
3016. Deputy Réada Cronin asked the Minister for Health if consideration will be given to adding Libre 2 PLUs patches to the long-term illness scheme for those transitioning from type 2 to type 1 diabetes; and if she will make a statement on the matter. [25382/26]
3068. Deputy Cathy Bennett asked the Minister for Health if her attention has been drawn to the use of the drug fampyra with regard to treating of ataxia within other EU member states; if consideration has been given to facilitating similar usage within Ireland; if so, the current status of any such considerations; the steps that a person can take to access fampyra for such treatment; and if she will make a statement…
3085. Deputy Cian O'Callaghan asked the Minister for Health if she is in favour of reimbursement pathways for GLP-1 therapies in obesity where clinically indicated; and if she will make a statement on the matter. [25785/26]